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Abstract For the analysis of gene function in vivo, gene
overexpression in the mouse provides an alternative to
loss-of-function knock-out approaches and can help reveal
phenotypes where compensatory mechanisms are at play.
Furthermore, when multiple lines overexpressing a gene-
of-interest at varying levels are studied, the consequences
of differences in gene dosage can be explored. Despite
these advantages, inherent shortcomings in the method-
ologies used for the generation of gain-of-function trans-
genic mouse models have limited their application to
functional gene analysis, and the necessity for multiple
lines comes at a significant animal and financial cost. The
targeting of transgenic overexpression constructs at single
copy into neutral genomic loci is the preferred method for
the generation of such models, which avoids the unpre-
dictable outcomes associated with conventional random
integration. However, despite the increased reliability that
targeted transgenic methodologies provide, only one
expression level results, as defined by the promoter used.
Here, we report a new versatile overexpression allele, the
promoter-switch allele, which couples PhiC31 integrase-
targeted transgenesis with Flp recombinase promoter
switching and Cre recombinase activation. These recom-
bination switches allow the conversion of different over-
expression alleles, combining the advantages of transgenic
targeting with tunable transgene expression. With this
approach, phenotype severity can be correlated with
transgene expression in a single mouse model, providing a
cost-effective solution amenable to systematic gain-of-
function studies.
Introduction
To explore gene function in vivo, there is a choice to be
made between loss-of-function and gain-of-function
strategies. Reducing a gene’s activity below a critical
threshold frequently yields insights into gene function and
has been widely adopted due to the availability of Knock-
out mutants via international consortia (Bradley et al.
2012) and, more recently, the use of nuclease technology
has facilitated their generation (Wang et al. 2013). These
strategies, however, can be challenging when exploring
families of genes with similar function as compensatory
effects by related family members can mask phenotypes
(Barbaric et al. 2007). A gain-of-function approach fre-
quently overcomes these redundancy problems and has
proven to be an informative strategy for the analysis of
gene function in many model organisms (Prelich 2012).
Despite the potential utility, gene overexpression in the
mouse remains a cumbersome approach, mainly due to the
methodologies used in model generation. The traditional
approach, pronuclear injection, results in the random inte-
gration of the transgenic construct at varying copy number
(Palmiter et al. 1986). This uncontrolled event can lead to
mutagenesis (Beier et al. 1989), and frequently, transgene
expression is influenced by sequences flanking the inte-
gration site (Dobie et al. 1996; Hatada et al. 1999). Mul-
tiple independent lines must be characterized to causally
link phenotype with transgene expression, resulting in a
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high animal and financial cost. Although independent lines
expressing the transgene at differing levels can allow
phenotype severity to be correlated with the level of
transgene expression, this fortuitous outcome is infre-
quently obtained.
Several ‘‘targeted transgenic’’ methodologies have been
established to overcome the problems of random insertion
which allow transgenes to be introduced at single copy into
defined loci, permissive for transgene expression (Bronson
et al. 1996; Soriano 1999). Endogenous and exogenous
promoters have been used to drive transgene expression
ubiquitously (Farley et al. 2000) and in a Cre recombinase-
dependent manner (Nyabi et al. 2009), and their production
has been facilitated by recombinase-mediated cassette
exchange (RMCE) methodologies to increase the effi-
ciency of site specific insertion (Hitz et al. 2007; Seibler
et al. 2005). These approaches all lead to a more pre-
dictable outcome, yet only a single line of mice is gener-
ated with only one level of expression as defined by the
promoter used. Exploring gene dosage with this method
thus necessitates the generation of multiple lines of mice,
made with different promoters, again resulting in high
animal and financial cost.
Here we report the development of an improved targeted
transgenic methodology which generates a more versatile
overexpression allele, which we call the promoter-switch
allele, capable of driving transgene expression condition-
ally and at two different expression levels. The method
allows the advantages of transgenic targeting approaches to
be combined with an ability to explore the effects of
transgene dosage, yet only a single line of mice need be
generated per construct. Using our system, transgenes are
efficiently targeted to the neutral ROSA26 (Gt(ROSA)26-
Sor) locus via PhiC31 integrase RMCE (Chen et al. 2011)
where their expression is initially silenced. Upon Cre
recombinase activation, the transgene expression becomes
linked to the strong CAG promoter, allowing conditional
tissue-specific transgene overexpression. The action of Flp
recombination then substitutes the strong CAG promoter
(Niwa et al. 1991) for the weaker ROSA26 promoter (So-
riano 1999) allowing the effects of more moderate trans-
gene expression to be investigated (Fig. 1a).
Materials and methods
Generation of the RS-PhiC ES cell line
For the promoter-switch docking site, a targeting vector
previously used to equip the ROSA26 locus for PhiC31
integrase cassette exchange, pRosa26.10 (Hitz et al. 2007),
was adapted by firstly replacing the FRT-attP-PGK-Hygro-
attP-30-homology arm-dTA, released as a PacI-KpnI
fragment with a synthesized AsiSI-KpnI linker, FRT-MfeI-
PacI-SalI-EcoRI-attP-XhoI-NsiI. Into the MfeI-PacI sites of
this vector, the CAG promoter, released as an EcoRI-PacI
fragment from pCAG-C31(NLS)-bpA (Hitz et al. 2007),
was cloned, generating plasmid pRosa-CAG. An assembly
of Hygro-E2A-PhiC31-integrase-P2A-dsRed-SV40-pA
was generated by fusion PCR using pRosa26.10 as a tem-
plate for the Hygromycin selection cassette, pPGKPhi-
C31obpA (Addgene #13795) as a template for a murine
codon-optimized PhiC31 integrase and pSIREN-DNR-
dsRed-Express (Clontech) as a template for the dsRed-
SV40 pA and cloned into the SalI-EcoRI sites in pRosa-
CAG. The 30 homology arm and dTA negative selection
cassette from pROSA26.10 were released as a SacII-KpnI
fragment and inserted into the same sites in a cloning vec-
tor, pKO Scrambler 924 (Stratagene), allowing its release as
an XhoI fragment and subsequent insertion into the XhoI
site of the above assembly, completing the final targeting
vector. The final vector included a dsRed cassette linked to
the PhiC31 integrase by a P2A self-cleaving peptide.
Although the CAG-Hygro-E2A-PhiC31 integrase-P2A-
dsRed-pA construction yielded red fluorescence when tes-
ted in transient transfection of HEK293T cells, upon
genomic integration, no dsRed fluorescence above back-
ground levels could be detected. Since this fluorescent
cassette is not relevant for the method, the cassette has been
omitted from the main figures for clarity. The targeting
vector was linearized by NsiI digestion and electroporated
into 1 9 107 JM8F6 cells at 500 V, 3 lF. Cells were plated
on mitotically inactivated mouse embryonic fibroblasts,
prepared from DR4 homozygous embryos, and recombinant
clones were recovered by selection in 75 lg/ml Hygro-
mycin. Homologously recombined clones were identified
by long-range PCR at the 50 end using a forward primer,
R26-5F1, binding upstream of the homology region (50-
GGCACTACTGTGTTGGCGGA-30) and a reverse primer,
R26-5R1, binding in the inserted splice acceptor sequence
(50-GGCCAGCTTATCGATACCGT-30) which yielded a
1.6 kb product (Supplementary Fig. 1c, d). Recombination
at the 30 end was then confirmed by long-range PCR using a
forward primer, PhiC31-F1, binding within the PhiC31
integrase cassette (50-CACCGGCCCCAAGTCCTGGT-30)
and a reverse primer, Rosa3-R1, binding downstream of the
30 homology arm (50-CTCAGTGGCTCAACAACACTTG
GTCA-30) which yielded a 7.2 kb product (Supplementary
Fig. 1c, e). Single copy integration of the vector was con-
firmed by Southern blot analysis using a probe against
hygromycin. The targeted ROSA26 locus was attributed the
allele name Gt(ROSA)26Sortm1(CAG-Hygro-PhiC31)Wthg. The
targeting vector used to generate the cassette exchange-
tagged ROSA26 locus has been deposited at Addgene
(Cambridge, USA), and the RS-PhiC ES cell line is avail-
able from the authors on request.
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Construction of promoter-switch exchange vectors
A 160 bp XmaI fragment, encoding a 30 portion of attB-
FRT-loxP-PstI-NsiI-loxP-XhoI, was synthesized and
cloned between the XmaI sites in pCB92 (Chen et al.
2011). This reconstituted the 50 attB site and allowed the
ORF of the neomycin phosphotransferase gene together
with the bovine growth hormone polyadenylation sequence
(obtained from pCB92) to be inserted between the loxP
sites in the resulting vector via the PstI-NsiI sites. A
polylinker of unique restriction sites, allowing easy cloning
of transgenes, was then added together the 30 attB site as a
synthesized linker via the XhoI site, creating the promoter-
switch exchange vector pCB93.
Fig. 1 Overexpression of GFP in ES cells and mice. a Key steps in
the generation of the promoter-switch mice. b Lower panel shows the
ROSA26 locus tagged with the PhiC31 integrase docking site. Upper
panel shows the CB93 exchange vector with the transgene of interest
positioned downstream of the loxP-flanked Neomycin cassette (Neo).
c The ROSA26 allele following the PhiC31 integrase-mediated
cassette exchange with (d) ES cell GFP expression silenced. e The
ROSA26 allele following transgene activation by Cre recombinase
yielding (f) strong ES cell GFP expression. g The ROSA26 allele
following the CAG promoter deletion by Flp recombinase, coupling
transgene expression to the ROSA26 promoter and yielding (h) a
visibly lower level of ES cell GFP expression. i Quantification of ES
cell GFP fluorescence before and after Cre and Flp recombinases.
j Spleen (Sp), lung (Lu), kidney (Ki), brain (Br), liver (Li) and heart
(He) GFP expression before recombinase action; k after Cre
recombinase activation and (l) after Flp recombinase promoter
switching
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To generate the GFP exchange construct, an eGFP-
rabbit-beta-globin-pA sequence was obtained from pCx-
eGFP as an EcoRI-HindIII fragment and cloned into the
polylinker of pCB93, creating plasmid pCB93-eGFP. For
the Nonagouti exchange construct, the mouse open reading
frame was amplified from image clone 3154863 (Source
Bioscience) using primers NA-F1 (50-CGAATTCGTGCT
GCTTCTCAGGATGGATG-30) and NA-R1 (50- AAGAA
TTCTCAGCAGTTGGGGTTGAGTACTC-30), which added
EcoRI overhangs and was then used to replace the eGFP
sequence in pCB93-eGFP via the EcoRI sites, creating
plasmid pCB93-NA. The two exchange vectors, CB93-
eGFP and CB93-NA have been deposited with Addgene
(Cambridge, USA)
PhiC31 integrase-mediated cassette exchange
1 9 106 RS-PhiC ES cells were electroporated with 5 lg of
exchange plasmid using the Neon transfection system (Life
Technologies) (3 9 1400 V, 10 ms) and plated on mitoti-
cally inactivated mouse embryonic fibroblasts, prepared
from DR4 homozygous embryos. After approximately
7 days of selection in 210 lg/ml G418, 24 resistant colonies
were isolated per construct, expanded and screened for the
correct cassette exchange event at the 50 end, using a for-
ward primer, CAG-F (50-CAGCCATTGCCTTTTATGG
T-3, binding within the CAG promoter, upstream of the 50
att site) and a reverse primer, ExNeo2 (50-GTTGTGCCCA
GTCATAGCCGAATAG-30), binding within the exchange
vector in the neomycin selection cassette, to yield a 589 bp
product, and at the 30 end, using a forward primer, att-F1
(50-GCACTAGTTCTAGAGCGATCCCC-30), binding at
the very 30 end of the exchange vector and a reverse primer,
3HR-R1 (50-CGGGAGAAATGGATATGAAGTACTGGG
C-30), binding downstream of the 30 att site, to yield a
511 bp product (Supplementary Fig. 2c).
Cre and Flp transient transfections
1 9 106 ES cells harbouring the GFP promoter-switch
allele were transiently transfected with either 5 lg of
pCrePac (Taniguchi et al. 1998) or pFlpO (Addgene
#13793) using the Neon transfection system (Life Tech-
nologies) (3 9 1400 V, 10 ms) and plated at low density
on mitotically inactivated mouse embryonic fibroblasts.
Individual colonies were isolated and screened for the
deletion event. Recombined GFP clones were identified by
PCR using a reverse primer, GFP-NR3, binding within the
eGFP ORF (50-ACACGCTGAACTTGTGGCCG-30) and
either the CAG-F primer to yield a 622 bp product in Cre
recombinase-deleted clones (Supplementary Fig. 2d) or a
forward primer, del-ROSA-F1 (50-CAGCCATTGCCTTTT
ATGGT-30), binding upstream of the splice acceptor to
yield a 652 bp product in Flp recombinase-deleted clones
(Supplementary Fig. 2e).
Quantification of ES cell eGFP fluorescence
Cells were observed using a Zeiss confocal laser micro-
scope (LSM, Carl Zeiss Microscopy) with a 63 9 lens.
During imaging of different groups of cells, the same
system configuration was used, keeping all parameters
fixed, including laser power, laser line, dichroic beam
splitter for separating excitation and emission, pinhole size
and scanning speed. GFP expression was quantified using
the MetaMorph software (Molecular Devices). The average
signal intensity of each cell was measured by tracing
around individual cells. Average intensity over all of the
cells was computed as the mean of all signal intensity
values from each cell.
Animals
Mice were housed in individually ventilated cages and
received food and water ad libitum. All studies received
local ethical review approval and were performed in
accordance with UK Home Office Animals (Scientific
Procedures) Act 1986. Cre-deleter mice (Tg(Pgk1-cre)1Lni
(Lallemand et al. 1998)), inducible Cre-deleter mice
(Gt(ROSA)26Sortm2(cre/ERT2)Brn (Hameyer et al. 2007)),
Flp-deleter mice (Tg(ACTB-Flpe)9205Dym (Jax stock
005703)), and KRT14-Cre mice (Tg(KRT14-cre)1Amc/J
(Jax stock 004782) were all maintained on a C57BL/6J
background. For comparisons of weight gain, sample sizes
of 7 male and 9 female mice for strong overexpression
(?Cre -Flp), 8 male and 6 female mice for weaker
overexpression (?Cre ?Flp) and 9 male and 16 female
non-expressing control mice (-Cre -Flp) were used. Fat
content was measured with an EchoMRI-100 Small Animal
Body Composition Analyzer, and GFP expression from
whole organs was monitored using ChemiDocTM XRS ?
System (Biorad). Statistically significant differences
between experimental groups at fixed age points were
tested with the Student’s t test. Cre-ERT2 activation was
induced by 5 daily 100 ll i.p. injections of 4-hydroxyta-
moxifen dissolved in corn oil (Sigma) at a dose of 75 mg/
kg body weight.
Mouse production and deleter matings
A single line of ES cells harbouring the GFP promoter
switch (E04) and a single line of ES cells harbouring the
Nonagouti promoter-switch allele (B04) were microin-
jected into albino C57BL/6J (Jax stock 000058) blasto-
cysts, and a chimaera showing[90 % ES cell contribution
was obtained in both cases. The chimaeras were mated
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with albino C57BL/6J females, and germline transmission
was confirmed in the F1 generation by the presence of
black pups. These were genotyped with the primer com-
bination used for PhiC31 integrase-mediated cassette
exchange. An F1 heterozygote harbouring the promoter-
switch allele was obtained in the 1st litter (GFP) or the 2nd
litter (Nonagouti) following test crossing of these chi-
maeras. These F1 mice were then bred with Cre-deleter
mice, and successful deletion of the loxP-flanked neomycin
selection cassette was detected by PCR as described above
for eGFP promoter-switch allele. For the Nonagouti pro-
moter-switch allele, Cre-deleted clones were identified
using the CAG-F primer in combination with the NA-R1
primer, yielding a 944 bp product (Supplementary
Fig. 3b), and Flp-deleted clones were identified using the
del-Rosa-F1 primer in combination with the NA-R1 pri-
mer, yielding a 974 bp product (Supplementary Fig. 3c).
To remove the recombinase transgenes and avoid the
complication of mosaicism resulting from incomplete
deletion events, the Cre- and Flp-deleted lines were
backcrossed with C57BL/6J prior to analysis and targeted
transgenic mice which had not inherited the recombinase
transgenes were taken for further analysis. Southern blot
analysis was performed on genomic DNA from mice har-
bouring the Cre-deleted allele and the Flp-deleted allele
which validated the recombination events and excluded the
possibility of multiple integration of the original exchange
plasmid in the lines (data not shown).
Expression analysis
Total RNA was isolated from homogenized tissue (Qi-
ashredder, Qiagen) using the RNeasy Mini Kit (Qiagen),
and first-strand cDNA was synthesized using Tetro reverse
transcriptase (Bioline) as per manufacturer’s instructions
using 500 ng of total RNA. Q-PCR analysis of Nonagouti
transcripts was performed using the primer pair (50-CTTCC
AAGAAAAAGGCTTCG-30 and 50- ATTCTCAGCAGTT
GGGGTTG-3) with normalization against two house-
keeping genes: Hprt (50-AGCTACTGTAATGATCAGTC
AACG-30 and 50-AGAGGTCCTTTTCACCAGCA-30) and
Gapdh (50-TGCGACTTCAACAGCAACTC-30 and 50-CT
TGCTCAGTGTCCTTGCTG-30) using the Power SYBR
Green PCR Master mix (Applied Biosystems) and a BioRad
CFX96 cycler as per manufacturer’s instructions. Relative
expression was calculated using the Livak method.
Tissues were pulverized on dry ice and lysed in 50 mM
Tris, 150 mM NaCl, 0.5 % Triton X100 containing pro-
tease inhibitors (complete, EDTA-free Protease Inhibitor
Cocktail, Roche) at 4 C for 20 min, followed by cen-
trifugation and removal of the non-soluble pellet. Protein
concentrations were quantified using the Bicinchoninic
acid (BCA) protein assay kit (Pierce). 30 lg of whole cell
lysate was loaded into each well of an Amersham ECL
8–16 % Polyacrylamide gel (GE Healthcare) and blotted
onto a nitrocellulose membrane using standard protocols.
Mouse monoclonal antibody against eGFP (Roche
#11814460001) and mouse monoclonal antibody against a-
tubulin (Tat-1; Sigma #00020911) were used for protein
detection.
Results
Preparation of the docking site cell line
and the RMCE exchange vector
A C57BL/6 ES cell line, RS-PhiC, harbouring a docking
site for PhiC31 integrase-mediated cassette exchange at the
ROSA26 locus was prepared by gene targeting (Fig. 1b and
Fig. S1). A CAG promoter-driven hygromycin resistance
and PhiC31 integrase construct were targeted to intron 1 of
the ROSA26 locus. PhiC31 attP sites were positioned
around the Hygro-E2A-PhiC31 coding region, constituting
the docking site for the subsequent cassette exchange. A
splice acceptor and an FRT site were included upstream of
the CAG promoter to allow transgenes to be coupled to the
endogenous ROSA26 promoter (see below).
An exchange vector, CB93, harbouring a loxP-flanked
promoterless neomycin resistance cassette upstream of a
polylinker into which transgenes can be cloned, flanked by
PhiC31 attB sites, was prepared (Fig. 1b). An additional
FRT site was included upstream of the floxed neomycin
cassette which provides the basis of the promoter switching
in subsequent steps.
In vitro proof-of-concept using an eGFP reporter
in ES cells
As a first test, GFP was cloned into CB93, and the resulting
exchange vector was electroporated into RS-PhiC ES cells.
PhiC31 integrase expressed from within the docking site
catalysed the recombination between the genomic attP sites
and the exchange vector attB sites, leading to an exchange
of the Hygro-E2A-PhiC31 integrase cassette for the FRT-
loxP-Neo-loxP-eGFP cassette (Fig. 1b and Fig. S2a–c),
conveying G418 resistance. The presence of the PhiC31
expression cassette obviates the need to introduce exoge-
nous integrase to mediate exchange and the exchange event
leads to the excision of the cassette itself. Consequently,
the efficiency of the cassette exchange event is very high
and, routinely following electroporation of 1 9 106 RS-
PhiC ES cells, several hundred G418 resistant colonies
were obtained. Similar to our previously reported results
with a PhiC31 cassette exchange system at ROSA26 (Chen
et al. 2011), all G418 resistant clones represent a targeted
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integration event, with approximately 70 % of the colonies
harbouring a true exchange event (50 and 30 attP 9 attB
recombination occurring), the remaining 30 % had inte-
grated the entire vector via a single 50 attP 9 attB
recombination event. The system thus allows a targeted
integration efficiency of at least 1 9 10-4 with respect to
the cell population electroporated.
Correct exchange led to the GFP cassette being posi-
tioned downstream of the CAG promoter (previously used
to drive the Hygro-E2A-PhiC31 integrase expression)
(Fig. 1c). Expression of eGFP was initially hindered by the
presence of the loxP-flanked neomycin cassette, the
polyadenylation sequence of which blocks transcription
(Fig. 1d). To test the Cre-dependent activation of transgene
expression, cassette-exchanged clones were transiently
transfected with Cre recombinase. Strong GFP expression
resulted in Cre-deleted clones due to the excision of the
neomycin cassette, linking the strong CAG promoter to
GFP (Fig. 1e, f). Next, the Flp recombinase promoter
switch was tested by transiently transfecting the Cre-
deleted clones with Flp recombinase. Flp recombinase
excised the FRT-flanked CAG promoter, linking the GFP
to the endogenous ROSA26 promoter via the splice
acceptor lying within intron 1 (Fig. 1g). GFP expression in
the resulting Flp-deleted clones was visibly weaker
(Fig. 1h), and quantification of the fluorescence change
revealed a level approximately 6.4-fold lower than in non-
Flp-recombined clones (Fig. 1i).
In vivo proof-of-concept using an eGFP reporter
promoter in mice
Having demonstrated that the Cre recombinase activation
and Flp recombinase promoter switching leads to robust
transgene expression at two different expression levels in
ES cells, the system was then tested in vivo. A mouse line
harbouring the GFP promoter-switch allele was prepared
by blastocyst injection of cassette-exchanged ES cells and
breeding of the resulting chimaeras. As expected, these
mice were not found to express GFP, due to the presence of
the loxP-flanked neomycin cassette (Fig. 1j). On breeding
with Cre-deleter mice (Fig. S2d), deleted offspring strongly
expressed GFP under the control of the CAG promoter
(Fig. 1k). These mice were then bred with Flp-deleter mice
(Fig. S2e), and Flp-deleted offspring expressed GFP at a
considerably lower level (Fig. 1l). GFP expression was
analysed across several organs by Western blot analysis
which confirmed the visible difference in expression level
before and after Cre and Flp recombinase switching
(Fig. 2), with CAG-driven expression being considerably
stronger than the ROSA26 driven expression in all tissues
studied.
Correlation of a visible phenotype and expression
level in a Nonagouti promoter-switch model
To establish whether this method can be used to help
functional analysis by allowing the severity of a phenotype
to be correlated with transgene expression, mice harbour-
ing the cDNA of the Nonagouti peptide in the promoter-
switch allele were generated (Fig. S3). The peptide
antagonizes the binding of alpha-melanocyte stimulating
hormone to the melanocortin-1 receptor, switching melanin
synthesis in the hair follicle from the black eumelanin to
the yellow pheomelanin pigment (Bultman et al. 1992).
Overexpression thus yields a discernible coat colour phe-
notype, as exemplified by several yellow mouse strains
whose coat colour is due to Nonagouti gain-of-function
(Miller et al. 1993).
Before Cre recombinase treatment, mice harbouring the
non-activated promoter-switch allele were black in coat
colour and indistinguishable from wild-type litter mates.
When these mice were crossed with Tg(KRT14-Cre), mice
which express Cre recombinase in melanocytes, offspring
showing a characteristic strong agouti colouring were
obtained (Fig. 3a). When these mice were crossed with
Flp-deleter mice, a more subtle agouti colour resulted
(Fig. 3b). Transgene expression analysis in KRT14-Cre-
activated mice confirmed transgenic Nonagouti expression
in the skin, where the KRT14-Cre transgene is active, but,
not in other tissues, where the KRT14-Cre transgene is not
expressed, such as brain and spleen (Fig. 3c). Furthermore,
differences in Nonagouti expression levels within the skin
before and after Flp recombinase-mediated promoter
switching, were consistent with expression driven by the
strong CAG promoter (before Flp recombination) or the
weaker ROSA26 promoter (after Flp recombination) and
the visible differences in coat colour before and after Flp
expression correlated with these observed levels of skin
expression (Fig. 3d). These results visibly demonstrate the
flexibility of the promoter-switch methodology for
achieving tissue-specific transgene expression at two dif-
ferent dosages.
To explore the versatility of the system in temporal
control of transgene expression, a ubiquitous tamoxifen-
inducible Cre recombinase transgene was introduced by
breeding the non-recombined Nonagouti mice with
Gt(ROSA)26Sortm2(Cre-ERT2)Brn mice. The mice harbouring
both transgenes were black in coat colour and indistin-
guishable from wild-type litter mates. Double-transgenic
mice were injected with 4-hydroxytamoxifen and after
2 weeks, inducible activation of strong Nonagouti over-
expression became evident from the growth of yellow hair.
Yellow hair growth progressed for the next 3–4 weeks until
the mice became almost entirely yellow in appearance
(Fig. 3e, f, g). The temporal activation of expression using
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Fig. 2 Western blot analysis of
brain, spleen, lung, liver, heart
and kidney of mice harbouring
the eGFP overexpression allele
before and after the activation
by Cre recombinase and after
the promoter switching by Flp
recombinase. eGFP and a-
tubulin were detected with
molecular weights of
approximately 28 and 55 kDa,
respectively
Fig. 3 Testing the promoter-switch allele with a visible phenotype.
a Mice harbouring the Nonagouti overexpression allele, with (right)
and without (left) the Tg(KRT14-Cre) transgene. b Mice harbouring
the Cre-activated Nonagouti overexpression allele, before (left) and
after (right) the action of Flp recombinase. c Quantification of
transgenic Nonagouti transcripts in the skin, brain and spleen of
Krt14-Cre-activated Nonagouti overexpressing mice. d Quantification
of transgenic Nonagouti transcripts in the skin before and after the
action of Cre and Flp recombinase. e, f, g Mice harbouring the
Nonagouti overexpression allele with a tamoxifen-inducible Cre-
ERT2 transgene at 19, 31 and 48 days following the injection of
4-hydroxytamoxifen (?4-OH-T) or vehicle (-4-OH-T)
604 H. Dolatshad et al.: A versatile transgenic allele for mouse overexpression studies
123
this simple coat colour marker highlights the strict non-
leaky control of transgene expression which is achievable
with the promoter-switch method.
Correlation of a quantifiable phenotype
and expression level in a Nonagouti
promoter-switch model
In the above example, the different intensities of coat col-
our demonstrate the consequences of different gene dosages
of Nonagouti overexpression, but we were keen to explore
a more quantifiable phenotype to fully validate the tech-
nique for correlating phenotype and expression. Nonagouti
is also known to antagonize members of the melanocortin
receptor family outside of the skin follicle and within the
hypothalamus, ectopic Nonagouti overexpression results in
obesity (Klebig et al. 1995). To test the promoter-switch
allele with this quantifiable phenotype, a ubiquitous Cre-
deleter mouse was used to activate transgene expression in
all tissues. These mice were then bred with Flp-deleter
mice to switch the promoter. It quickly became apparent
that Nonagouti-expressing mice at both expression levels
were prone to obesity, but significantly the weight gain
occurred at a faster rate when the transgene expression was
under the control of the stronger CAG promoter, as com-
pared to the weaker ROSA26 promoter (Fig. 4a and
Fig. S4). These mice were analysed for body fat content at
approximately 16 weeks of age, and a significant associa-
tion between the strength of the promoter used and body fat
was found (Fig. 4b). Transgene expression, now ubiqui-
tously activated, was quantified in two example tissues,
brain and spleen and, as expected, Flp-deleted mice were
found to express Nonagouti approximately sixfold and
sevenfold lower than the non-Flp-deleted mice (Fig. 4c, d).
Thus, the degree of weight gain and fat deposition, i.e. the
severity of the phenotype was found to correlate with the
two levels of transgene expression achieved with the pro-
moter-switch methodology.
Discussion
It is clear from numerous human pathologies that abnormal
gene activation or copy number (Girirajan et al. 2011),
which frequently leads to increased gene expression,
underlies human disease states. Indeed the causative SNPs
emerging from genome-wide association studies frequently
map to regulatory sequences (Maurano et al. 2012; Schaub
et al. 2012) and are thus thought to exert their effects by
altering gene expression. How these expression changes
contribute to altered cell physiology leading to disease
progression remains largely unexplored. Our robust pro-
moter-switch methodology focussed on exploring gene
overexpression at different gene dosages is thus of con-
siderable application in dissecting the molecular mecha-
nisms underlying these potentially pathogenic increases in
gene expression.
Current methods for gene overexpression in the mouse
are rather blunt instruments as they provide only a single-
expression level per line. Traditionally, random integration
approaches have been adopted with simple promoter cDNA
or Bacterial Artificial Chromosome-based constructs which
lead to multiple lines of mice, each with a unique copy
number and site of integration. This method is sometimes
able to yield different lines with different levels of
expression with which the consequences of gene dosage
can be explored; however, this fortuitous outcome is
infrequently obtained as high copy number transgene
arrays are frequently associated with variegation and
silencing (Garrick et al. 1998). Transgenic targeting—the
targeting of overexpression constructs to defined permis-
sive loci—overcomes a lot of these problems but to obtain
different expression levels, multiple lines with different
promoters much still be generated. Irrespective of the
methodology used for their generation, while being highly
informative, the study of multiple lines necessitates the
generation, breeding and characterisation of several mouse
models which come at a significant animal and frequently
prohibitive financial cost.
Our promoter-switch methodology combines the
advantages of transgenic targeting with two recombinase
switches allowing a flexibility to change overexpression
dosage thus providing versatile overexpression models
with only a single line of mice required per gene. The first
switch is a Cre recombinase activation which can be used
to turn on strong transgene overexpression in specific target
tissues and cell types, as defined by the expression pattern
of the Cre driver, or activation can occur at a specific time
point through the use of inducible Cre recombinase lines.
Cre recombinase expressing lines are freely available
within the scientific community (Nagy et al. 2009), and
international consortia have been funded to streamline their
production (Chandras et al. 2012). The second switch is
provided by the action of a binary (on/off) Flp recombinase
to change overexpression dosage and is achieved by simple
breeding with a ubiquitously expressed Flp recombinase-
deleter line, many of which are widely available (Birling
et al. 2012; Rodriguez et al. 2000). For clarity, the pro-
moter-switch method does not envisage the use of tissue-
specific Flp recombinase expressing mice, which are rarely
available, only a Flp-deleter mouse needs to be used for the
promoter switch as the tissue specificity is provided by the
Cre recombinase activation step.
The two levels of overexpression achieved by this
methodology reflect the activities of a single copy of a
CAG promoter- or a ROSA26 promoter-driven expression
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construct. Although these promoters are considered to
direct broadly ubiquitous expression, tissue-specific dif-
ferences in expression level have been observed for
reporters driven by the CAG (Kawamoto et al. 2000) and
the ROSA26 (Kisseberth et al. 1999) promoters. Consis-
tently, in our promoter-switch models, we observed tissue-
specific differences in the relative expression levels, as
exemplified by the variation in eGFP expression between
Fig. 4 Correlating gene
overexpression with phenotype
severity. a Growth curves for
female Nonagouti
overexpression mice before
(green diamonds; n = 16) and
after (blue squares; n = 9)
ubiquitous Cre recombinase
activation and following the Flp
recombinase promoter switch
(red triangles; n = 6). b Body
fat composition analysis of
female and male Nonagouti
overexpression mice before and
after ubiquitous Cre
recombinase activation and
following the Flp recombinase
promoter switch. c,
d Quantification of transgenic
Nonagouti transcripts in the
brain and spleen of mice before
and after ubiquitous Cre
recombinase activation and
following the Flp recombinase
promoter switch. p values were
calculated with the Student’s
t test using weights and body fat
composition at 110 days of age
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tissues and by the varying ratios of CAG versus ROSA26
promoter-driven transcript levels quantified in ES cells,
skin, brain and spleen, before and after Flp recombinase
promoter switching. Although it is important to consider
these tissue-specific differences in relative expression
levels before and after promoter switching, it is clear that
CAG-driven expression is considerably stronger than the
ROSA26-driven expression in all tissues.
The two different expression levels achievable with the
promoter-switch methodology provide considerable flexi-
bility when studying the effects of gene overexpression.
Where a phenotype is only apparent after a certain
threshold of overexpression is exceeded, the promoter-
switch approach allows the consequences of very strong
overexpression to be studied by simple Cre activation
(without the Flp recombinase promoter switch). Con-
versely, for example, where genes are associated with an
adverse phenotype or where the endogenous expression
level of a gene is low, it might be more appropriate and
biologically relevant to consider a milder level of overex-
pression. With the promoter-switch methodology, per-
forming the Flp recombinase promoter switch in advance
of tissue-specific Cre activation allows a weaker level of
overexpression to be achieved. Phenotype and expression
level are rarely linearly correlated, and subsequently our
promoter-switch method which achieves two extremes of
gene overexpression in a single mouse model provides
considerable utility for probing gene function.
The cassette exchange approach at the heart of the
promoter-switch method would be amenable to high-
throughput applications and systematic screening studies.
The constitutive expression of the PhiC31 integrase
enzyme from within the cell line, driving the transgene
integration event and the concomitant deletion of the
integrase in correctly targeted clones, streamlines the
whole production process and greatly increases the effi-
ciency of targeted insertion by avoiding the necessity to
introduce exogenous integrase. With our system, we report
targeted integration efficiencies of at least 1 9 10-4 with
respect to the starting ES cell population electroporated,
2–3 orders of magnitude above the rates recorded for
conventional gene targeting.
With respect to conversion of the ES cell resource into
mouse lines, with the two lines prepared in this study,
chimaeras with over 90 % ES cell contribution (by coat
colour) were obtained for both projects following a single
injection session and transfer of a single foster mother with
microinjected embryos. Germline transmission was
obtained for both ES cell lines by breeding just a single
chimaera. The results we obtained in this study compare
favourably with our experience of targeted ES cell clones
generated on the JM8F6 background, for example, those
obtained from the International Knock-out Mouse
Consortium (IKMC) resource, and are consistent with the
production efficiencies reported by other laboratories
working with this parental line (Pettitt et al. 2009). Labo-
ratories having gained experience with the IKMC resource
would therefore be expected to be able to work with cas-
sette-exchanged RS-PhiC ES cells using the standard
conditions recommended for JM8F6 ES cell injection
(https://www.komp.org/protocols.php). For an even faster
production, previous studies have used a PhiC31 integrase
RMCE approach directly in the oocyte, through the co-
microinjection of the exchange vector together with
PhiC31 integrase mRNA in zygotes genetically harbouring
the docking site (Ohtsuka et al. 2010). Our promoter-switch
allele could be generated in this fashion, and future studies
will address the feasibility of implementing this refined
technique, obviating the need for ES cell work.
Mouse breeding can be a potential bottle neck in func-
tional analysis and the allelic conversion, i.e. activation of the
transgene by Cre recombinase and, when required, the
switching of promoter strength by Flp recombinase would
indeed require further mouse generations. However, since
only a single (heterozygous) copy of the promoter-switch
allele is required for strong overexpression, the first experi-
mental cohorts of mice with Cre-activated strong overex-
pression, together with their necessary controls, would be
available within a single generation (3–4 months). Where
ubiquitous activation is appropriate, techniques exploring the
use of cell-permeable recombinases for allelic conversion, as
reported for the Knock-out first alleles (Ryder et al. 2014)
could be applied to speed up the availability of cohorts.
In summary, the promoter-switch approach has proven
to be a robust, reliable and versatile method of studying
gene overexpression. Firstly, the PhiC31 integrase-medi-
ated cassette exchange approach provides an efficient
means of generating targeted transgenic lines and is par-
ticularly well suited for the comparison of multiple lines of
mice expressing variant transgenes. Secondly, spatiotem-
poral transgene overexpression can be achieved through
the use of tissue-specific and inducible Cre recombinase
expressing mice. Thirdly, through the use of Flp-deleter
mice, two lines of mice can be generated allowing strong
overexpression, driven by the CAG promoter, to be com-
pared with more moderate expression levels, driven by the
endogenous ROSA26 promoter. Thus, a single line of mice
needs only to be generated per transgene, and through a
series of simple crosses with recombinase expressing lines,
informative overexpression models can be generated,
allowing phenotypic severity to be correlated with gene
dosage.
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